Evidence map›Paper›PMID 18343128›Full record

ArticleBioorganic & medicinal chemistry2009

Beta-turn secondary structure and melanocortin ligands.

Erica M Haslach, Jay W Schaub, Carrie Haskell-Luevano

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Erica M HaslachDepartment of Medicinal Chemistry, University of Florida, PO Box 100485, Gainesville, FL 32610, USA.
Jay W Schaub
Carrie Haskell-Luevano
University of Florida · US

Funding

STRUCTURAL DETERMINANTS OF NEUROENDOCRINE RECEPTORSR01DK057080 · NIDDK · UNIVERSITY OF FLORIDA · PI HASKELL-LUEVANO, CARRIE · 2000 to 2008
$2.7M
Endogenous G-Protein Coupled Receptor AntagonistsR01DK064250 · NIDDK · UNIVERSITY OF MINNESOTA · PI HASKELL-LUEVANO, CARRIE · 2003 to 2012
$2.6M
Human Melanocortin-4 Receptor PolymorphismsR01DK063974 · NIDDK · UNIVERSITY OF FLORIDA · PI HASKELL-LUEVANO, CARRIE · 2004 to 2007
$975k
NIDDK NIH HHS R01 DK057080NIDDK NIH HHS R01 DK063974NIDDK NIH HHS R01DK063974NIDDK NIH HHS R01 DK064250NIDDK NIH HHS R01DK57080NIDDK NIH HHS R01DK64250
6 · The paper itself

Abstract

The melanocortin pathway has emerged during this past decade as an important target area for the discovery and development of therapeutic agents related to obesity and type 2 diabetes. This peptide-G-protein coupled receptor (GPCR) pathway has evolved from peptide-based ligands to small molecules possessing a variety of different molecular scaffolds. Herein, we summarize the originating hypothesis of the importance of the reverse beta-turn secondary structure for agonist ligand potency at the melanocortin receptors and how that information was utilized for the discovery of small molecules based upon this type of turn structure.

Indexed as

Amino Acid SequenceLigandsMelanocortinsProtein Structure, SecondaryReceptors, MelanocortinStereoisomerismLigandsMelanocortinsReceptors, Melanocortin

Identifiers

PMID18343128
PMCPMC2662475
OpenAlexW2120326008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.